Compare AUPH & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | PRGO |
|---|---|---|
| Founded | 1993 | 1887 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 1999 | 1991 |
| Metric | AUPH | PRGO |
|---|---|---|
| Price | $15.20 | $13.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $17.25 | ★ $22.00 |
| AVG Volume (30 Days) | 1.1M | ★ 4.2M |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 8.33% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.55 | N/A |
| Revenue | $265,808,000.00 | ★ $4,281,800,000.00 |
| Revenue This Year | $21.76 | N/A |
| Revenue Next Year | $16.45 | N/A |
| P/E Ratio | $28.99 | ★ N/A |
| Revenue Growth | ★ 20.62 | N/A |
| 52 Week Low | $6.55 | $12.17 |
| 52 Week High | $16.54 | $30.93 |
| Indicator | AUPH | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 43.08 | 50.19 |
| Support Level | $15.64 | $13.63 |
| Resistance Level | $15.98 | $14.07 |
| Average True Range (ATR) | 0.39 | 0.39 |
| MACD | -0.13 | 0.23 |
| Stochastic Oscillator | 13.73 | 91.97 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.